MINIREVIEW
Defining Ca2+/Calmodulin-dependent Protein Kinase Cascades in Transcriptional Regulation*

Ethan E. Corcoran and Anthony R. MeansDagger

From the Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710



    INTRODUCTION
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES

Calcium is a well established regulator of transcription. Modulation of responses to this ubiquitous second messenger can occur by superposition of coincident Ca2+-independent signals, but there is also growing evidence that the strength, frequency, source, and location of the Ca2+ signal are determinants for specific transcriptional results. These complex variations must be translated into changes in protein function that preserve and process the information conveyed by the original signal. The Ca2+ receptor calmodulin (CaM)1 is involved in many of these changes through its effects on a variety of CaM-binding proteins (1). Among these, the multifunctional Ca2+/calmodulin-dependent protein kinases (CaMKs) are notable for their effects on components of transcription complexes, directly connecting Ca2+ with changes in gene expression. The highly homologous CaMKI and CaMKIV are distinct from the multimeric CaMKII, although all have broad and overlapping substrate preferences, because their activation is greatly enhanced following phosphorylation catalyzed by "upstream" kinases in a manner analogous to the mitogen-activated protein kinase cascade. Based on an evolving understanding of CaMKI/IV regulation and cloning of the CaMKI/IV kinases (CaMKKs), a Ca2+/CaM-dependent protein kinase I/IV cascade (CaMK cascade) has been proposed (2, 3). This review will discuss the biochemical and physiologic basis for the existence of this cascade and its potential for mediating Ca2+ regulation of transcription.


    Identification and Biochemical Characterization of a CaMK Cascade
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES

CaMKI and CaMKIV are closely related protein kinases with many similarities in mode of activation and substrate preferences in vitro but with different tissue distributions. The kinases are regulated by Ca2+/CaM binding, which relieves intramolecular steric inhibition of the active site by a C-terminal autoinhibitory domain (Fig. 1). A second autoinhibitory mechanism unique to CaMKIV is relaxed by the autophosphorylation of Ser-12 and Ser-13 (4). In addition to deinhibition, CaMKI and CaMIV are activated 10-50-fold by trans phosphorylation on a single Thr residue in the activation loop. Once activated, CaMKIV acquires Ca2+/CaM independence, whereas CaMKI remains Ca2+/CaM-dependent (5). Dephosphorylation and inactivation of activated CaMKI/IV can be catalyzed in vitro by PP1, PP2A, calcineurin (CaN), and the CaMK phosphatase, but the relevant phosphatase(s) in vivo is still unclear (6, 7). CaMKI is ubiquitously expressed, whereas CaMKIV has a more limited distribution, although both enzymes are strongly expressed in the brain.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Stages of CaMKI/IV activation and effects on activation-dependent (S) and activation-independent (S') substrates. For CaMKIV, autophosphorylation is also required in the first step but is not depicted.

Recognition of the ability of kinases in brain extract to phosphorylate and activate CaMKI/IV led to the cloning of two upstream kinases, CaMKKalpha and CaMKKbeta (8, 9). In addition to the brain, where both CaMKKs are highly expressed, CaMKKalpha mRNA is found in thymus and spleen, whereas CaMKKbeta is present at lower levels in all tissues that express CaMKIV. Although derived from distinct genes, rat CaMKKs are 80% similar, and either CaMKK can phosphorylate and activate CaMKI and CaMKIV in vitro. Both CaMKKs bind and are positively regulated by Ca2+/CaM in vitro, and although their CaM binding site is different from the other CaMKs, the autoinhibitory mechanism functions in a similar manner to that of other Ca2+/CaM-dependent kinases (10). Importantly, Ca2+/CaM binding to CaMKI/IV is a prerequisite to phosphorylation by the CaMKKs (5). Thus, in theory Ca2+/CaM could regulate CaMKI/IV activity on many levels.

The substrate preferences of CaMKI and CaMKIV are similar and intersect with CaMKII. In vitro, all three can phosphorylate synapsin I, cAMP response element-binding protein (CREB), and activating transcription factor 1 (11, 12). Their minimum consensus sequence Hyd-X-R-X-X-(S/T) (where Hyd is any hydrophobic amino acid), determined through peptide studies, provides only a rough template common to many protein kinases (11). Additional specificity is provided by residues adjacent to the phosphorylation site of the substrate, producing differences in substrate preference among these kinases. The differences can have important transcriptional implications; for example, although all three can phosphorylate CREB on the activating site Ser-133, only CaMKII phosphorylates an additional inhibitory site, Ser-142 (13).

Interestingly, the presence of two additional basic amino acids 6 and 7 residues N-terminal to the phosphorylation site in certain peptide substrates allows phosphorylation by CaMKI/IV equally well with or without activation by a CaMKK (14). This "activation independence" has not yet been demonstrated toward protein substrates. Nonetheless, because CaMKI/IV requires Ca2+/CaM for deinhibition in addition to activation loop phosphorylation, substrates of this type would not be phosphorylated by CaMKI/IV until a Ca2+ signal was initiated and so could represent Ca2+-dependent but activation-independent signaling targets. Subsequent activation by a CaMKK would increase the number of available substrates by enhancing CaMKI/IV activity toward a second set of substrates (Fig. 1).


    Does the Cascade Function in Cells?
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES

The first reconstruction of a CaMK cascade in cells used transient transfection experiments with CREB as the transcriptional target. CaMKI and CaMKIV phosphorylate CREB on its activating Ser-133 in vitro and stimulate Gal4-CREB-dependent transcription in response to a rise in intracellular Ca2+ when cells are cotransfected with Gal4-CREB and a Gal4 reporter gene (15). Additional cotransfection with a CaMKK increases reporter activity more than 10-fold (8, 9). Mutation of the CaMKIV activation loop T to A abolishes CaMKK enhancement.

To be a signaling cascade, kinase activation loop phosphorylation must be dependent upon induction of CaMKK activity. Phosphate incorporation into endogenous CaMKIV in Jurkat cells is induced rapidly following T-cell receptor stimulation and is blocked by chelation of extracellular Ca2+. This is accompanied by 8-14-fold increases in immunoprecipitated CaMKIV activity that is refractory to further activation by exogenous CaMKK and can be reversed by in vitro treatment with PP2A (16). Recombinant CaMKIV transfected into BJAB cells, which lack endogenous CaMKIV, demonstrates similar activation following anti-IgM stimulation that is abrogated by mutating the activation loop T to A (4). Likewise, CaMKI phosphorylation is induced in PC12 cells, coincident with increased CaMKI activity and reduced activation of CaMKI by exogenous CaMKK (17). Collectively, these experiments provide strong evidence for an inducible, Ca2+-dependent activation of CaMKI and CaMKIV in intact cells via activation loop phosphorylation. However, the fact that activation loop phosphorylation requires Ca2+ does not confirm that the physiologic activator is itself Ca2+-dependent, because Ca2+/CaM binding to CaMKI or CaMKIV is required before these enzymes can be phosphorylated by the known CaMKKs.

The issue of subcellular localization is a confounding one for any model of the CaMK cascade regulating transcription. There are several lines of evidence that CaMKKalpha and -beta are both cytoplasmic. In contrast to an early study using a polyclonal antibody, immunohistochemistry of rat brain slices using monoclonal antibodies able to distinguish between the alpha  and beta  isoforms found exclusively cytoplasmic immunoreactivity for both (18). Furthermore, green fluorescent protein-tagged CaMKKalpha and -beta are cytoplasmic in NG108 cells even after depolarizing stimulation (18). This holds true for overexpressed CaMKKbeta in Jurkat and BJAB cells.2 Similarly, CaMKI appears to be excluded from the nucleus in brain slices as well as in cells overexpressing the protein, yet CaMKI immunoreactivity has recently been observed to translocate to the nuclei of hippocampal neurons during long term potentiation (19, 20).3 In contrast, CaMKIV is predominantly nuclear but can also be found in neuronal soma and dendritic processes, where it could interact with a cytoplasmic CaMKK (21).

The CaMK cascade then is well positioned to affect cytoplasmic events, but it is more difficult to explain its effects on transcription. There could be changes in subcellular localization, an unidentified nuclear CaMKIV activator, or cytosolic CaMK cascade targets that modulate nuclear events. Whether full-length CaMKI enters the nucleus or affects transcription through a cytoplasmic intermediate has not been well studied, but it can stimulate transcription of reporters in transient transfection assays (15). Consequently, although the biochemistry is unambiguous and transient transfections appear to reconstruct a cascade, the mechanism for transcriptional regulation by a CaMK cascade in cells is more complicated than expected.

Several other pathways may influence or be influenced by the CaMK cascade. CaMKI and protein kinase A can phosphorylate CaMKKs on multiple inhibitory sites in vitro, and forskolin stimulation reduces CaMKI/IV activation in several cell lines (22). Likewise, nuclear localization of CaMKIIalpha B and delta B isoforms is inhibited by phosphorylation of their nuclear localization sequence by CaMKI or CaMKIV, presumably counteracting direct CaMKII effects on transcription (23). In addition, in vitro experiments indicate CaMKK can phosphorylate and activate both AMP kinase and protein kinase B, and the AMP kinase kinase can phosphorylate and activate CaMKI, although all of these effects are far less substantial than those of the accepted activators AMP kinase kinase, phosphoinositide-dependent kinase 1, and CaMKK, respectively (24-26). Finally, Ras-independent activation of the mitogen-activated protein kinases ERK2, p38, and JNK1 was observed in cells transfected with constitutively active CaMKIV and further enhanced by cotransfection with CaMKKalpha (27). The physiologic significance of interacting signal cascades is still unclear, but these examples do serve as a reminder of the intricacy of signal processing.


    Is the Cascade Physiologic?
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES

The evolutionary conservation of CaMKI/IV and CaMKK suggests a fundamental biological role. From Aspergillus nidulans to Caenorhabditis elegans to mammals, the cascade members are highly conserved and biochemically interchangeable in gross assays of cascade function in vitro (28, 29). Potential homologues have also been identified in Schizosaccharomyces pombe (30, 31) and Drosophila melanogaster (32). Investigating the CaMK cascade in genetically tractable systems will help determine whether it is a physiologic pathway and what biological functions it might regulate.

However, to assess the biological significance of the cascade, cellular targets must be identified. CREB is a likely possibility, as it can be activated by the CaMK cascade in transfection experiments (Fig. 2), but many kinases can be induced to phosphorylate CREB (33, 34). It seems likely that the physiologic kinase(s) depends on the situation. For example, expression of catalytically inactive, dominant negative CaMKIV (dnCaMKIV) specifically in developing thymocytes blocks CREB phosphorylation on Ser-133, leading to effects including decreased interleukin-2 production that are reminiscent of thymocytes from mice expressing dnCREB S133A (35). Yet, in initial experiments with thymocytes from CaMKIV-null mice, Ser-133 phosphorylation is subtly decreased but not prevented, and total interleukin-2 production appears normal.4 The most parsimonious explanation for these conflicting observations is that the dnCaMKIV prevented CREB phosphorylation not only by CaMKIV but also by other thymic CREB kinases. In contrast, CREB phosphorylation is severely reduced in both cerebellar extracts and stimulated hippocampal neurons of CaMKIV knockout mice but is unaffected in the testis (36-38). These results suggest that CaMKIV functions as a CREB kinase in some but not all tissues. Evaluation of CREB phosphorylation in the absence of CaMKKs awaits development of appropriate genetic models.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 2.   Modes of CREB regulation by CaMKIV.

Situation-specific signal regulation could be accomplished, in part, through regulated association of CaMKIV with other cellular components. An avid association between CaMKIV and PP2A has been demonstrated by copurification and coprecipitation; immunoprecipitated CaMKIV is nearly stoichiometrically associated with PP2A, although the reverse is not true because of the large excess of PP2A (39). Inhibition of PP2A with adenovirus small t antigen or okadaic acid increases CaMKIV-dependent activation of Gal4-CREB transcription, which could result from blocking dephosphorylation of CaMKIV, CREB, and/or CBP. In contrast to the apparently constitutive association of CaMKIV with a potential deactivator, attempts to coprecipitate CaMKIV and CaMKK have been unsuccessful, suggesting that the preformed signaling complex may not include the known activators.2 Although its significance is not understood, biochemical fractionation of testis extract indicates that a hyperphosphorylated form of CaMKIV is associated with the nuclear matrix (40). Targeting CaMKIV to appropriate loci in a preformed signaling complex could be an important factor in its effects on transcription. As the example of CREB phosphorylation in CaMKIV-null mice poignantly demonstrates, we cannot yet predict when a transcription factor that can be regulated by CaMKIV in transfected cells will be regulated by CaMKIV in vivo and how that specificity is determined.


    Other Transcriptional Targets of CaMKIV
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES

CaMKIV has been linked with the regulation of many transcription factors other than CREB, including AP-1, serum response factor, and activating transcription factor 1, and may have multiple modes of regulating CREB-dependent transcription (Fig. 2) (12). CREB transcriptional activation occurs through its binding to the coactivator protein CBP/p300, which links many transcription factors to components of the general transcriptional machinery. Phosphorylation of CREB on Ser-133 increases its affinity for CBP but whether CREB Ser-133 phosphorylation is sufficient to induce CRE-dependent transcription without other regulatory signals to CBP itself is controversial. Microinjection of phosphoserine 133-CREB or transfection with the Y134F CREB mutant that is constitutively phosphorylated induces CRE-dependent reporter plasmid transcription without additional stimuli (41, 42). Seemingly contradictory experiments demonstrate that induction of CRE-mediated transcription by depolarization of AtT20 cells requires nuclear Ca2+ but not increased CREB Ser-133 phosphorylation (43). Moreover, reporter gene transcription driven by a CREB-independent Gal4-CBP fusion is enhanced by constitutively active CaMKIV. Sites in CBP are inducibly phosphorylated, which has led to the hypothesis that CaMKIV regulates CBP by direct phosphorylation, but this remains to be demonstrated.

CaMKIV stimulation of transcription by the orphan receptor RORalpha may also be related to effects on coactivators. A CaMKIV effect on ROR was investigated because of the similarities in phenotypes between CaMKIV and RORalpha knockout mice. In transfection assays, CaMKIV induces a 20-30-fold increase in RORalpha -dependent transcription of a reporter plasmid (44). The RORalpha ligand binding domain (LBD) is not a substrate for CaMKIV in vitro, but LBD binding peptides that disrupt LBD association with endogenous coactivators abrogate the CaMKIV effect. Although the mechanism remains to be elucidated, these results and the CaMKIV effects on CBP suggest a new role for CaMKIV in recruiting or stabilizing coactivator-containing transcriptional complexes.

CaMKIV has also been implicated in the Ca2+-dependent regulation of MEF2 family transcription factors (Fig. 3). In cardiomyocytes and neurons, Ca2+ influx leading to MEF2 activation correlates with activation of p38, which phosphorylates MEF2 on multiple sites in vitro including those in its activation domain (45, 46). MEF2 has also been reported to be a substrate for CaMKIV in vitro (47). Constitutive forms of CaMKI/IV and CaN independently activate MEF2 reporter genes but synergize when cotransfected. There is evidence for two complementary mechanisms for the effect of CaN: dephosphorylation of NFAT, promoting its nuclear translocation and allowing it to synergize with MEF2 to activate reporter genes; and dephosphorylation of MEF2, which enhances its DNA binding (48). The coactivator CBP/p300 can bind both NFAT and MEF2 and may be involved in stabilizing a NFAT-MEF2 complex on the promoter and/or may itself be a target of a Ca2+-dependent stimulatory signal (49). Furthermore, Cabin-1, originally identified as a CaN inhibitor, also binds and suppresses MEF2 transcriptional activity in T-cells (50). Cabin-1 binding to MEF2 is competitive with p300 and is relieved by Ca2+/CaM binding to Cabin-1 (50, 51). Because Cabin-1 also associates with mSin3a and histone deacetylases 1 and 2 (HDAC1/2), its dissociation from MEF2 may replace a repressing complex with an activating complex (51). In a like manner, MEF2 binds and is repressed by HDAC4 but is released by Ca2+/CaM binding to HDAC4 (52). Association of MEF2 with HDAC4/5 can also be inhibited by cotransfection with a constitutively active fragment of CaMKI/IV, which may provide an indirect mechanism for CaMKI/IV enhancement of MEF2 transcription (53). Clearly, Ca2+ regulation of MEF2 is multifaceted, involving both stimulatory phosphorylation/dephosphorylation and dissociation from transcriptional repressors.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Regulation of MEF2 by Ca2+ signaling and possible roles for CaMKIV.

Missing from many studies of CaMKIV and transcription is a characterization of CaMKK effects and differentiation between CaMKI and CaMKIV. Unfortunately, the kinase inhibitors currently available, KN62 and KN93, inhibit CaMKI, II, and IV similarly and so they cannot be used alone to define a role for a specific CaMK (54). Moreover, these drugs block voltage-dependent K+ currents at concentrations comparable with those used for CaMK inhibition, so results from the use of these inhibitors should be interpreted cautiously (55). Truncations of the kinases to form constitutively active forms are also frequently used to study transcription, but because this removes domains of the kinase whose functions are unknown, these proteins could be inappropriately localized or regulated. For example, the CaMKIIalpha -(1-290) activating truncation also removes the association domain and thus both changes its activation biochemistry and permits inappropriate nuclear entry (2, 11). For CaMKI and CaMKIV, functions of the C-terminal region are not as well defined but may also affect subcellular distribution and substrate preference. One alternative approach that circumvents these pitfalls but has not yet been extensively employed is to use mutations in the autoinhibitory domains identified for CaMKII, CaMKIV, and CaMKKs that allow Ca2+/CaM-independent activity without truncation (10, 56, 57). Finally, because understanding of the cascade is still so skeletal, it is not reasonable to assume that transcriptional effects attributed to CaMKIV are also regulated by the CaMKK without directly testing that hypothesis. These caveats should be kept in mind in interpreting the results of experiments designed to implicate one of the CaMKs in a CaMK cascade.


    Evidence for a CaMK Cascade
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES

The evidence for a working CaMK cascade regulating Ca2+-dependent transcription in cells is largely favorable but still circumstantial. CaMKI and CaMKIV are excellent substrates of the CaMKKs and are dramatically activated by activation loop phosphorylation that occurs following stimulation of intact cells. The tissue distributions of the CaMKKs appropriately overlap those of CaMKI and CaMKIV, but the question of subcellular localization still needs to be resolved. Whether the CaMKKs so far identified are the only kinases capable of activating CaMKI and CaMKIV is unknown.

If this cascade is physiologic, does it function as a signal integrator or as an amplification circuit? Of course, inducible phosphorylation by CaMKKs provides a mechanism for amplification. However, like CaMKII, these kinases have elaborate activation mechanisms that rely on a Ca2+ signal for multiple steps. For CaMKII, this complex activation biochemistry has been shown to differentiate stimulation frequencies (58), but no such evidence yet exists for the CaMK cascade. The suggestion from peptide experiments that CaMKI/IV might exhibit different substrate specificities before and after activation offers tantalizing possibilities for signal processing beyond amplification. Elements of the cascade also interact with a variety of other pathways, and the CaMKKs may have substrates other than CaMKI/IV. Therefore, both amplification and integration are possible roles for a CaMK cascade. The intricate regulation of these kinases provides many interesting possibilities for transmitting Ca2+ signals.


    ACKNOWLEDGEMENTS

We thank K. E. Winkler, J. D. Joseph, C. D. Kane, K. A. Anderson, and I. R. Asplin for helpful discussions and critical reading of the manuscript, and S. S. Hook and K. A. Anderson for permission to discuss unpublished data.


    FOOTNOTES

* This minireview will be reprinted in the 2001 Minireview Compendium, which will be available in December, 2001. This is the second article of four in the "Ca2+-dependent Cell Signaling through Calmodulin-activated Protein Phosphatase and Protein Kinases Minireview Series." Our research was supported by United States Army Grant DAMD17-97-1-7331(to E. E. C.) and National Institutes of Health Grants HD07503 and GM33976 (to A. R. M.).

Dagger To whom correspondence should be addressed: Dept. of Pharmacology and Cancer Biology, Duke University Medical Center, Box 3813, Durham, NC 27710. Tel.: 919-681-6209; Fax: 919-681-7767; E-mail: means001@mc.duke.edu.

Published, JBC Papers in Press, November 28, 2000, DOI 10.1074/jbc.R000027200

2 E. E. Corcoran and A. R. Means, unpublished data.

3 S. S. Hook and A. R. Means, unpublished data.

4 K. A. Anderson and A. R. Means, unpublished data.


    ABBREVIATIONS

The abbreviations used are: CaM, calmodulin; CaMK, Ca2+/calmodulin-dependent protein kinase; CaMKK, CaMKI/IV kinase; CaN, calcineurin; CREB, cAMP response element-binding protein; CBP, CREB-binding protein; CRE, cAMP response element; dn, dominant negative; ROR, retinoic acid-related orphan receptor; LBD, ligand binding domain.


    REFERENCES
TOP
INTRODUCTION
Identification and Biochemical...
Does the Cascade Function...
Is the Cascade Physiologic?
Other Transcriptional Targets...
Evidence for a CaMK...
REFERENCES


1. Chin, D., and Means, A. R. (2000) Trends Cell Biol. 10, 322-328[CrossRef][Medline] [Order article via Infotrieve]
2. Means, A. R. (2000) Mol. Endocrinol. 14, 4-13[Free Full Text]
3. Soderling, T. R. (1999) Trends Biochem. Sci. 24, 232-236[CrossRef][Medline] [Order article via Infotrieve]
4. Chatila, T., Anderson, K. A., Ho, N., and Means, A. R. (1996) J. Biol. Chem. 271, 21542-21548[Abstract/Free Full Text]
5. Haribabu, B., Hook, S. S., Selbert, M. A., Goldstein, E. G., Tomhave, E. D., Edelman, A. M., Snyderman, R., and Means, A. R. (1995) EMBO J. 14, 3679-3686[Abstract]
6. Kasahara, J., Fukunaga, K., and Miyamoto, E. (1999) J. Biol. Chem. 274, 9061-9067[Abstract/Free Full Text]
7. Kitani, T., Ishida, A., Okuno, S., Takeuchi, M., Kameshita, I., and Fujisawa, H. (1999) J. Biochem. (Tokyo) 125, 1022-1028[Abstract]
8. Tokumitsu, H., Enslen, H., and Soderling, T. R. (1995) J. Biol. Chem. 270, 19320-19324[Abstract/Free Full Text]
9. Anderson, K. A., Means, R. L., Huang, Q. H., Kemp, B. E., Goldstein, E. G., Selbert, M. A., Edelman, A. M., Fremeau, R. T., and Means, A. R. (1998) J. Biol. Chem. 273, 31880-31889[Abstract/Free Full Text]
10. Tokumitsu, H., Muramatsu, M., Ikura, M., and Kobayashi, R. (2000) J. Biol. Chem. 275, 20090-20095[Abstract/Free Full Text]
11. Schulman, H., and Braun, A. (1999) in Calcium as a Cellular Regulator (Carafoli, E. , and Klee, C., eds) , pp. 311-343, Oxford University Press, New York
12. Anderson, K. A., and Kane, C. D. (1998) Biometals 11, 331-343[CrossRef][Medline] [Order article via Infotrieve]
13. Sun, P., Enslen, H., Myung, P. S., and Maurer, R. A. (1994) Genes Dev. 8, 2527-2539[Abstract]
14. Hook, S. S., Kemp, B. E., and Means, A. R. (1999) J. Biol. Chem. 274, 20215-20222[Abstract/Free Full Text]
15. Sun, P., Lou, L., and Maurer, R. A. (1996) J. Biol. Chem. 271, 3066-3073[Abstract/Free Full Text]
16. Park, I. K., and Soderling, T. R. (1995) J. Biol. Chem. 270, 30464-30469[Abstract/Free Full Text]
17. Aletta, J. M., Selbert, M. A., Nairn, A. C., and Edelman, A. M. (1996) J. Biol. Chem. 271, 20930-20934[Abstract/Free Full Text]
18. Sakagami, H., Umemiya, M., Saito, S., and Kondo, H. (2000) Eur. J. Neurosci. 12, 89-99[CrossRef][Medline] [Order article via Infotrieve]
19. Picciotto, M. R., Zoli, M., Bertuzzi, G., and Nairn, A. C. (1995) Synapse 20, 75-84[Medline] [Order article via Infotrieve]
20. Ahmed, B. Y., Yamaguchi, F., Tsumura, T., Gotoh, T., Sugimoto, K., Tai, Y., Konishi, R., Kobayashi, R., and Tokuda, M. (2000) Neurosci. Lett. 290, 149-153[CrossRef][Medline] [Order article via Infotrieve]
21. Nakamura, Y., Okuno, S., Sato, F., and Fujisawa, H. (1995) Neuroscience 68, 181-194[CrossRef][Medline] [Order article via Infotrieve]
22. Matsushita, M., and Nairn, A. C. (1999) J. Biol. Chem. 274, 10086-10093[Abstract/Free Full Text]
23. Heist, E. K., Srinivasan, M., and Schulman, H. (1998) J. Biol. Chem. 273, 19763-19771[Abstract/Free Full Text]
24. Hawley, S. A., Selbert, M. A., Goldstein, E. G., Edelman, A. M., Carling, D., and Hardie, D. G. (1995) J. Biol. Chem. 270, 27186-27191[Abstract/Free Full Text]
25. Yano, S., Tokumitsu, H., and Soderling, T. R. (1998) Nature 396, 584-587[CrossRef][Medline] [Order article via Infotrieve]
26. Okuno, S., Kitani, T., Matsuzaki, H., Konishi, H., Kikkawa, U., and Fujisawa, H. (2000) J. Biochem. (Tokyo) 127, 965-970[Abstract]
27. Enslen, H., Tokumitsu, H., Stork, P. J., Davis, R. J., and Soderling, T. R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10803-10808[Abstract/Free Full Text]
28. Eto, K., Takahashi, N., Kimura, Y., Masuho, Y., Arai, K., Muramatsu, M. A., and Tokumitsu, H. (1999) J. Biol. Chem. 274, 22556-22562[Abstract/Free Full Text]
29. Joseph, J. D., and Means, A. R. (2000) J. Biol. Chem. 275, 38230-38238[Abstract/Free Full Text]
30. Rasmussen, C. D. (2000) J. Biol. Chem. 275, 685-690[Abstract/Free Full Text]
31. Rupes, I., Jia, Z., and Young, P. G. (1999) Mol. Biol. Cell 10, 1495-1510[Abstract/Free Full Text]
32. Xu, X. Z., Wes, P. D., Chen, H., Li, H. S., Yu, M., Morgan, S., Liu, Y., and Montell, C. (1998) J. Biol. Chem. 273, 31297-31307[Abstract/Free Full Text]
33. Shaywitz, A. J., and Greenberg, M. E. (1999) Annu. Rev. Biochem. 68, 821-861[CrossRef][Medline] [Order article via Infotrieve]
34. Bito, H., Deisseroth, K., and Tsien, R. W. (1997) Curr. Opin. Neurobiol. 7, 419-429[CrossRef][Medline] [Order article via Infotrieve]
35. Anderson, K. A., Ribar, T. J., Illario, M., and Means, A. R. (1997) Mol. Endocrinol. 11, 725-737[Abstract/Free Full Text]
36. Wu, J. Y., Ribar, T. J., Cummings, D. E., Burton, K. A., McKnight, G. S., and Means, A. R. (2000) Nat. Genet. 25, 448-452[CrossRef][Medline] [Order article via Infotrieve]
37. Ho, N., Liauw, J. A., Blaeser, F., Wei, F., Hanissian, S., Muglia, L. M., Wozniak, D. F., Nardi, A., Arvin, K. L., Holtzman, D. M., Linden, D. J., Zhuo, M., Muglia, L. J., and Chatila, T. A. (2000) J. Neurosci. 20, 6459-6472[Abstract/Free Full Text]
38. Ribar, T. J., Rodriguiz, R. M., Khiroug, L., Wetsel, W. C., Augustine, G. J., and Means, A. R. (2000) J. Neurosci. 20, 1-5[Abstract/Free Full Text]
39. Westphal, R. S., Anderson, K. A., Means, A. R., and Wadzinski, B. E. (1998) Science 280, 1258-1261[Abstract/Free Full Text]
40. Wu, J. Y., and Means, A. R. (2000) J. Biol. Chem. 275, 7994-7999[Abstract/Free Full Text]
41. Alberts, A. S., Arias, J., Hagiwara, M., Montminy, M. R., and Feramisco, J. R. (1994) J. Biol. Chem. 269, 7623-7630[Abstract/Free Full Text]
42. Du, K., Asahara, H., Jhala, U. S., Wagner, B. L., and Montminy, M. (2000) Mol. Cell. Biol. 20, 4320-4327[Abstract/Free Full Text]
43. Chawla, S., Hardingham, G. E., Quinn, D. R., and Bading, H. (1998) Science 281, 1505-1509[Abstract/Free Full Text]
44. Kane, C. D., and Means, A. R. (2000) EMBO J. 19, 691-701[Abstract/Free Full Text]
45. Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M., and Greenberg, M. E. (1999) Science 286, 785-790[Abstract/Free Full Text]
46. Zhao, M., New, L., Kravchenko, V. V., Kato, Y., Gram, H., di Padova, F., Olson, E. N., Ulevitch, R. J., and Han, J. (1999) Mol. Cell. Biol. 19, 21-30[Abstract/Free Full Text]
47. Blaeser, F., Ho, N., Prywes, R., and Chatila, T. A. (2000) J. Biol. Chem. 275, 197-209[Abstract/Free Full Text]
48. Olson, E. N., and Williams, R. S. (2000) Bioessays 22, 510-519[CrossRef][Medline] [Order article via Infotrieve]
49. Youn, H. D., Chatila, T. A., and Liu, J. O. (2000) EMBO J. 19, 4323-4331[Abstract/Free Full Text]
50. Youn, H. D., Sun, L., Prywes, R., and Liu, J. O. (1999) Science 286, 790-793[Abstract/Free Full Text]
51. Youn, H. D., and Liu, J. O. (2000) Immunity 13, 85-94[Medline] [Order article via Infotrieve]
52. Youn, H. D., Grozinger, C. M., and Liu, J. O. (2000) J. Biol. Chem. 275, 22563-22567[Abstract/Free Full Text]
53. Lu, J., McKinsey, T. A., Nicol, R. L., and Olson, E. N. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4070-4075[Abstract/Free Full Text]
54. Hidaka, H., and Yokokura, H. (1996) Adv. Pharmacol. 36, 193-219[Medline] [Order article via Infotrieve]
55. Ledoux, J., Chartier, D., and Leblanc, N. (1999) J. Pharmacol. Exp. Ther. 290, 1165-1174[Abstract/Free Full Text]
56. Mukherji, S., Brickey, D. A., and Soderling, T. R. (1994) J. Biol. Chem. 269, 20733-20738[Abstract/Free Full Text]
57. Tokumitsu, H., Brickey, D. A., Glod, J., Hidaka, H., Sikela, J., and Soderling, T. R. (1994) J. Biol. Chem. 269, 28640-28647[Abstract/Free Full Text]
58. De Koninck, P., and Schulman, H. (1998) Science 279, 227-230[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.